Andrea Demitrovičová
The frequency of invasive fungal infections has increased dramatically because of an expanding population at risk. Treatment options for invasive mycoses have been primarily amphotericin B, fluconazole and itraconazole. Amphotericin B has wide antifungal activity but its toxicity is limiting factor for the treatment. To circumvert adverse effect, three lipid-formulated products were marked by encapsulating amphoterin B within lipid structures. Fluconazol has more favourable interaction and adverse-effect profil but acts only to Candida spp, Cryptococcus neoformans and some endemic fungi. Extensive spectrum of activity has itraconazol, but its pharmacokinetics and drug-drug interaction limit its using in lifethreating infections. The recent approval of voriconazole, posaconazole and caspofungin has expanded the number of existing antifungal drugs available, however these drugs are expensive and clinical experiences are limited